Arlington Capital Partners Acquires Virgo Publishing
Â
PHOENIX -- Virgo Publishing announces that it has been acquired by Arlington Capital Partners, a Washington, D.C.-based private-equity fund with more than $1 billion of committed capital under management.Â
Arlington Capital Partners is a middle market private equity firm focused on buyouts and recapitalizations in targeted growth industries in partnership with management. The firm leverages a combination of private equity and operating experience, as well as an extensive network of strategic contacts, enabling Arlington to be a value-added partner and investor.
Arlington Partners is pleased to partner with CEO Jenny Bolton and the Virgo management team. The team at Virgo has built an extraordinary track record over the last 20 years, and we look forward to our partnership during the next phase of the companys growth, said Perry Steiner of Arlington Capital.
Founded in 1986 and based in Phoenix, Virgo publishes 17 national trade magazines and produces 10 trade shows and conferences across several industry groups including natural products and healthcare, telecommunications and business solutions. Virgo is the producer of SupplySide -- the largest show in the world for innovative and healthy ingredients. The company has been successful in leveraging its category-leading events, publications and electronic media to provide integrated solutions to the markets it serves and will continue to focus on expansion through key, strategic acquisitions.
Virgo Publishing has an accomplished and experienced management team and will continue to be led by its president and CEO, Jenny Bolton. The entire publishing, events and online organization will also remain intact.Â
Regarding the acquisition by Arlington, Bolton commented, We are very excited about our new relationship with Arlington Capital Partners. Their contacts, financial expertise and acquisition experience make them an invaluable partner during this time of accelerated growth for the company. Arlington brings a rich combination of operating and private equity experience that we believe will enable them to be a truly 'value-added' investor.Â
Â
Â
Â
Outbreak Detection, Patient Protection: The Legal Upside of Genomics in Infection Prevention
May 21st 2025A string of infections following routine knee surgeries in Tennessee has escalated into litigation, raising questions about how—and when—health care facilities should detect outbreaks. As genomic surveillance gains traction in infection prevention, some fear it could increase legal risk. In reality, it may offer hospitals their strongest legal defense.
Silent Saboteurs: Managing Endotoxins for Sepsis-Free Sterilization
Invisible yet deadly, endotoxins evade traditional sterilization methods, posing significant risks during routine surgeries. Understanding and addressing their threat is critical for patient safety.